CA3255077A1 - AMORPHIC AND CRYSTALLINE FORMS OF MCI-1 ANTAGONISTS - Google Patents

AMORPHIC AND CRYSTALLINE FORMS OF MCI-1 ANTAGONISTS

Info

Publication number
CA3255077A1
CA3255077A1 CA3255077A CA3255077A CA3255077A1 CA 3255077 A1 CA3255077 A1 CA 3255077A1 CA 3255077 A CA3255077 A CA 3255077A CA 3255077 A CA3255077 A CA 3255077A CA 3255077 A1 CA3255077 A1 CA 3255077A1
Authority
CA
Canada
Prior art keywords
amg
crystalline form
amorphous
crystalline
xrpd pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3255077A
Other languages
English (en)
French (fr)
Inventor
Yosup Rew
Van Luu
Manuel Zancanella
Mary CHAVES
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CA3255077A1 publication Critical patent/CA3255077A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA3255077A 2022-04-05 2023-04-05 AMORPHIC AND CRYSTALLINE FORMS OF MCI-1 ANTAGONISTS Pending CA3255077A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263327656P 2022-04-05 2022-04-05
US63/327,656 2022-04-05
PCT/US2023/017505 WO2023196361A1 (en) 2022-04-05 2023-04-05 Amorphous and crystalline forms of mci-1 antagonists

Publications (1)

Publication Number Publication Date
CA3255077A1 true CA3255077A1 (en) 2023-10-12

Family

ID=86386948

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3255077A Pending CA3255077A1 (en) 2022-04-05 2023-04-05 AMORPHIC AND CRYSTALLINE FORMS OF MCI-1 ANTAGONISTS

Country Status (9)

Country Link
US (1) US20240140966A1 (enExample)
EP (1) EP4504738A1 (enExample)
JP (1) JP2025511331A (enExample)
AU (1) AU2023250874A1 (enExample)
CA (1) CA3255077A1 (enExample)
MX (1) MX2024012195A (enExample)
TW (1) TW202404982A (enExample)
UY (1) UY40218A (enExample)
WO (1) WO2023196361A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4519271A1 (en) 2022-05-04 2025-03-12 Gilead Sciences, Inc. Salts and polymorphs of certain mcl-1 inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3474B1 (ar) 2014-08-29 2020-07-05 Amgen Inc مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
KR20230113577A (ko) * 2020-11-25 2023-07-31 암젠 인크 알데히드의 거울상이성질체 선택적 알케닐화

Also Published As

Publication number Publication date
US20240140966A1 (en) 2024-05-02
TW202404982A (zh) 2024-02-01
WO2023196361A1 (en) 2023-10-12
MX2024012195A (es) 2024-11-08
EP4504738A1 (en) 2025-02-12
JP2025511331A (ja) 2025-04-15
AU2023250874A1 (en) 2024-10-10
UY40218A (es) 2023-10-13

Similar Documents

Publication Publication Date Title
AU2010274012A1 (en) Crystalline forms of N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy] -quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide
EP3022209B1 (en) Dolutegravir potassium salt
EP3873894B1 (en) Novel salt of a bcl-2 inhibitor, related crystalline form, method for preparing the same and pharmaceutical compositions containing the same
US20240140966A1 (en) Amorphous and crystalline forms of mcl-1 antagonists
KR20240119192A (ko) 2-(5-(4-(2-모르폴리노에톡시)페닐)피리딘-2-일)-n-벤질아세트아미드의고체 형태
US12351588B2 (en) Salt forms and solvates of Mcl-1 antagonists
US20250115622A1 (en) Crystalline Forms Of An MCL-1 Inhibitor
CA3222661A1 (en) Novel crystalline form of 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-n-methylazetidin-3-amine hemisuccinate
US20250122224A1 (en) Crystalline Salt and Solvate Forms Of Murizatoclax (AMG 397)
AU2009325147B2 (en) 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)] heptacosa-1(25),2(26),3,5,8,10,12(27)j16,21,23-decaene citrate salt
US12612405B2 (en) Crystalline form of 1-(8-Bromopyrido[2,3-E][1,2,4]triazolo[4,3-a]pyrazin-4-Yl)-Nmethylazetidin-3-amine hydrogen sulfate monohydrate
CN109843880B (zh) 4-(2-((1r,2r)-2-羟基环己基氨基)苯并噻唑-6-基氧基)-n-甲基吡啶酰胺的晶型
TW202216726A (zh) 八氫噻吩并喹啉化合物之琥珀酸鹽及其結晶
AU2023343417B2 (en) Psilocin crystalline forms
WO2018172950A1 (en) Anhydrous crystalline forms of sodium (s)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinolinecarboxylate
WO2024069576A1 (en) Novel crystalline form of 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-n-methylazetidin-3-amine mono succinate
TW202423429A (zh) 1-(8-溴化吡啶并[2,3-e][1,2,4]三唑并[4,3-a]吡嗪-4-基)-n-甲基吖丁啶-3-胺之鹽及結晶形式之製備方法以及新穎的結晶形式
WO2016127962A1 (en) An amorphous solid form of suvorexant with sulphuric acid
CA3219303A1 (en) Crystalline form of tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same
HK40060608A (en) Novel salt of a bcl-2 inhibitor, related crystalline form, method for preparing the same and pharmaceutical compositions containing the same
HK40060608B (en) Novel salt of a bcl-2 inhibitor, related crystalline form, method for preparing the same and pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240924

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250213

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250213

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250213

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250220

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED

Effective date: 20250327

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250327

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250331

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250331

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260319

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260319